Five months after ending development of its own obesity treatment, Pfizer is accelerating its push into the rapidly growing field with a nearly $5-billion acquisition.

Stocks closed broadly higher as Wall Street navigates through the uncertainty of a trade war.

Chinese Premier Li Qiang says Beijing and Washington should choose dialogue instead of confrontation.

Pfizer's CEO Albert Bourla is trying to reposition the global pharmaceutical giant for a post-pandemic world.

The fallout from the Israel-Hamas war has spilled into workplaces everywhere, with corporate leaders from the highest ranks of prominent companies weighing in with their views while workers complain their voices are not being heard.

Pfizer is spending about $43 billion to reach deeper into new cancer treatments that target tumor cells while sparing surrounding healthy tissue.

Pfizer says it will provide nearly two dozen products at not-for-profit prices in some of the world’s poorest countries.

Sales of Pfizer’s COVID-19 vaccine and treatment pushed the drugmaker well past expectations in the first quarter, as profit grew 61%.

Pfizer's chief executive, Albert Bourla, has been awarded the prestigious Genesis Prize for his efforts in leading the development of a COVID-19 vaccine.

The U.S. has given full approval to the COVID-19 vaccine made by Pfizer.

In early 2020, the coronavirus was spreading across the globe and nobody knew how to stop it.

Japan’s prime minister met with Pfizer’s CEO in an unusually high-profile setting to make sure the drugmaker would deliver COVID-19 vaccine it has promised to the nation.

The husband and wife team who helped develop the first COVID-19 vaccine are contributing to a book.

Pfizer Chairman and CEO Dr. Albert Bourla can now look back and tell the incredible story.

A U.S. health panel says it’s time to resume use of Johnson & Johnson’s COVID-19 vaccine, despite a very rare risk of blood clots.

Japan's prime minister has asked U.S. drug maker Pfizer for additional supplies of the COVID-19 vaccine.

I know what it’s like to not be there when it happens," said Biden, who has long addressed grief more powerfully than perhaps any other American public figure. "I know what it’s like when you are there, holding their hands, as they look in your eye and they slip away. In one of his many symbolic breaks with his predecessor, Biden has not shied away from offering remembrances for the lives lost to the virus. The COVID-19 death total in the United States had just crossed 400,000 when Biden took the oath of office. Outside of perfunctory tweets marking the milestones of 100,000 and 200,000 deaths, Trump oversaw no moment of national mourning, no memorial service.

In giving the go-ahead for emergency use of the vaccine developed by American drugmaker Pfizer and Germany’s BioNTech, Britain vaulted past the United States by at least a week. Officials cautioned that several tough months still lie ahead even in Britain, given the monumental task of inoculating large swaths of the population. Hancock said Britain will begin receiving the first shipment of 800,000 doses from Belgium within days, and people will start getting the shots as soon as it arrives. Still to be determined is whether the Pfizer-BioNTech shots prevent people from spreading the virus when they have no symptoms. ___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education.

The Education Ministry says about 493,430 students began taking the one-day test at about 1,380 test sites across South Korea on Thursday. The university from which a South Korean graduates significantly affects job prospects, social standings and even marriage partners. Health care workers, citizens above 65 and people living in care homes will be the first groups to be vaccinated. Redfield says earlier surges in COVID-19 illnesses were concentrated in one area of the country or another, and health care workers and equipment could be shifted from one place to another to deal with it. ___TORONTO — Canada’s health minister says health officials will soon complete a review of the coronavirus vaccine made by Pfizer and BioNTech.

“This is one of the most significant medical advances in the last 100 years,” Dr. Albert Bourla, Pfizer Chairman and CEO, said. El Sahly actually oversees the Moderna trial for Baylor College of Medicine. Americans will receive the vaccine for free consistent with the U.S. government’s commitment for free access for COVID-19 vaccines." Some infectious disease experts, including Dr. Peter Hotez with Baylor College of Medicine, believe the first vaccine available may not be the one that’s proven most effective in the long run. “I’m often asked the question, ‘hey Dr. Hotez which vaccine are you waiting for?’ That’s the wrong question I’m not waiting for anything,” Hotez explained.

Pfizer released no specific breakdowns, but for the vaccine to be 90% effective, nearly all the infections must have occurred in placebo recipients. REPORT 90% EFFECTIVE. But in July, Pfizer signed a contract to supply the U.S. with 100 million doses for $1.95 billion, assuming the vaccine is cleared by the FDA. Earlier this year, Fauci said he would be happy with a COVID-19 vaccine that was 60% effective. Pfizer has estimated it could have 50 million doses available globally by the end of 2020, enough for 25 million people.

Pfizer executives had expected data from their 44,000-person international study would show by Oct. 31 how well it prevents coronavirus infections. Analysts peppered Bourla and other Pfizer executives with so many questions about the study that he repeatedly asked for their patience. It expects revenue of $48.8 billion to $49.5 billion, narrowed from its previous forecast of $48.6 billion to $50.6 billion. Pfizer will receive about $12 billion in return and its shareholders will get roughly one Viatris share for each Pfizer share they own. Pfizer expects to be able to grow revenue at least 6% annually through 2025 as a result of the transformation.

NEW YORK – Pfizer Inc. cannot request emergency authorization of its COVID-19 vaccine before the third week of November -- and that’s if everything goes well, the company’s CEO announced Friday. Another leading U.S. contender, Moderna Inc., previously announced the earliest it could seek authorization of its own vaccine would be Nov. 25. Pfizer CEO Albert Bourla has long said it's possible testing might reveal by the end of October if his company’s vaccine actually protects against the coronavirus. The vaccine made by Pfizer and its German partner BioNTech are among several leading candidates in final testing. ___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education.

Despite top U.S. federal health officials repeatedly stating that a vaccine is unlikely to be available widely until mid-2021, President Donald Trump has insisted that a vaccine will be ready before Election Day. “I’ve spoken to Pfizer, I’ve spoken to all of the people that you have to speak to, Moderna, Johnson & Johnson, and others. “It’s become very political.”“We’re weeks away from a vaccine,” Trump added. Johnson & Johnson just started the final study of its vaccine last week. ___Follow Linda A. Johnson at https://twitter.com/LindaJ_onPharma___The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Department of Science Education.